CD3 Antibodies Targeting F2B Epitope for Reduced Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CD3-based bispecific antibodies for cancer therapy induce high toxicity due to non-specific T-cell activation and cytokine release syndrome, limiting their clinical development.
Innovation Solution
Development of antibodies that bind to the F2B epitope on CD3, minimizing cytokine release while maintaining effective tumor cell lysis, by optimizing binding affinity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD3-based bispecific antibodies are used to activate T cells for cancer therapy, then anti-tumor effects are improved, but toxicity due to non-specific T-cell activation and cytokine release increases
Solution Approach 1:
The patent applies local quality by targeting a specific epitope (F2B) on the CD3 molecule with high precision, rather than activating all CD3 sites. This localized approach ensures that T cell activation occurs only at the specific binding site, reducing non-specific activation and associated toxicity while maintaining effective anti-tumor activity.
Solution Approach 2:
The patent changes the binding affinity parameter by optimizing the antibody's interaction with the F2B epitope. By fine-tuning the binding strength (KD value) to achieve optimal engagement without excessive activation, the patent reduces cytokine release and toxicity while preserving tumor-killing capability.
2Reliability
If high affinity anti-CD3 antibodies are used to ensure strong T cell activation, then tumor lysis is improved, but cytokine release syndrome increases
Solution Approach 1:
The patent applies partial action by using an antibody that binds with sufficient affinity to activate T cells effectively, but not so strongly as to cause excessive cytokine release. The F2B epitope-targeting antibody provides just enough activation to achieve tumor lysis while avoiding the harmful effects of over-activation.
Solution Approach 2:
The patent converts the potential harm of strong CD3 activation into a benefit by selectively targeting the F2B epitope, which provides controlled activation. This approach transforms what could be harmful non-specific activation into beneficial specific activation that spares normal tissues.
3Reliability
If conventional anti-CD3 antibodies are used for therapy, then T cell activation is achieved, but binding affinity is suboptimal resulting in ineffective signaling
Solution Approach 1:
The patent changes the binding affinity parameter by designing an antibody with optimized interaction with the F2B epitope. This results in enhanced binding strength and more effective T cell signaling compared to conventional antibodies, while maintaining safety through controlled activation.
Data Source
AI summary
Novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases are provided, as well as bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.